Control Bionics Ltd. (CBL) AI Stock Analysis

• Market Cap: AU$9.13M
• Dividend Yield: N/A
• Average Volume (3M): 113.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: -7.44%
• EPS Growth: 30.34%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 294,611,100
• 10 Day Avg. Volume: 136,222
• 30 Day Avg. Volume: 113,227
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: AU$0.00 ▼(-100.00%Downside)

Control Bionics Ltd. is currently facing significant financial difficulties with declining revenues and persistent losses impacting its overall financial performance. Technical indicators also point towards a bearish trend, and the valuation metrics highlight unprofitability. These factors collectively result in a low overall stock score.

Control Bionics Ltd. Business Overview & Revenue Model

Company Description

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.

How the Company Makes Money

Control Bionics Ltd. (CBL) generates revenue primarily through the sale of its assistive technology devices, such as the NeuroNode Trilogy and NeuroNode Duo. These products are sold directly to consumers, healthcare providers, and institutions, and are often funded through insurance reimbursements, government support programs, or personal purchase. Additionally, the company may earn revenue from ongoing service and support contracts, training, and customization services for its technology solutions. Strategic partnerships with healthcare organizations and technology distributors can also contribute to its earnings by expanding market reach and facilitating product adoption.

Control Bionics Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
5.13M	5.44M	4.38M	3.93M	3.10M
	Gross Profit
3.67M	3.50M	2.40M	2.50M	215.51K
	EBIT
-5.93M	-5.62M	-6.09M	-3.52M	-1.20M
	EBITDA
-5.01M	-5.14M	-5.58M	-3.40M	-989.96K
	Net Income Common Stockholders
-5.91M	-5.63M	-6.11M	-4.19M	-1.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
980.76K	935.50K	5.21M	12.33M	15.60M
	Total Assets
9.03M	8.70M	13.44M	18.35M	20.51M
	Total Debt
961.74K	128.50K	284.82K	14.87K	46.00K
	Net Debt
-19.02K	-807.00K	-4.93M	-12.32M	-15.55M
	Total Liabilities
2.76M	1.55M	1.51M	1.19M	387.00K
	Stockholders Equity
6.27M	7.15M	11.92M	17.16M	20.13M
Cash Flow		Free Cash Flow
-5.38M	-4.98M	-5.75M	-4.04M	-1.17M
	Operating Cash Flow
-4.91M	-4.53M	-5.60M	-3.99M	-864.05K
	Investing Cash Flow
-473.09K	-457.54K	-147.74K	-53.40K	-301.85K
	Financing Cash Flow
5.43M	706.43K	-87.33K	14.92M	1.79M

Control Bionics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.18 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CBL.

Control Bionics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RHT	61 Neutral	AU$17.47M	140.00	-3.11%	―	89.13%	69.57%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
PYC	53 Neutral	AU$691.16M	―	-112.97%	―	―	-84.82%
1AD	46 Neutral	AU$2.68M	―	-392.18%	―	―	34.26%
CBL	39 Underperform	AU$9.13M	―	-98.08%	―	-7.44%	30.34%
CALZF		$529.71M	136.61	8.30%	―	―	―
OPL	35 Underperform	AU$4.93M	―		―	-67.78%	37.66%

Control Bionics Ltd. Corporate Events

Control Bionics to Host Investor Webinar Amid Product Expansion

Control Bionics Limited announced an investor webinar to discuss its quarterly results and recent advancements. The company is enhancing its market position with innovative products like the NeuroNode and DROVE, and is expanding into new sectors with the NeuroStrip®, potentially impacting its operations and stakeholder interests.

Control Bionics Announces Director Departure and Shareholding Impact

Control Bionics Ltd. announced the cessation of Peter Ford as a director effective March 31, 2025. Ford held a significant number of ordinary shares, totaling 20,003,433, which may influence the company’s shareholder dynamics. This change in directorship could impact the company’s strategic direction and governance, potentially affecting stakeholders’ interests.

Control Bionics Appoints New Director with Significant Shareholding

Control Bionics Ltd has announced the appointment of Stephanie Phillips as a director effective March 25, 2025. Phillips holds significant interests in the company, with 149,998 ordinary shares registered in her name and an additional 3,700,000 shares held through Ironwood Investments Pty Ltd. This appointment and Phillips’ substantial shareholding could influence the company’s strategic direction and strengthen its market position.

Control Bionics Announces Board Changes: Welcomes Dr. Stephanie Phillips, Bids Farewell to Founder Peter Ford

Control Bionics Limited has announced the appointment of Dr. Stephanie Phillips to its Board of Directors, bringing her extensive experience in anaesthesia and critical care to the company. Her expertise is expected to significantly contribute to Control Bionics’ expansion into new markets in assistive communication, rehabilitation, and health diagnostics. Concurrently, the company announced the resignation of its founder, Peter Ford, from the Board, effective March 31, 2025. Ford’s pioneering work led to the development of the NeuroNode technology, which has been transformative in the assistive technology sector. While stepping down, Ford remains a significant shareholder, ensuring his continued influence on the company’s future.